alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 27 studies in Long-term cohort studies with an author at University College London (GB) (page 1 of 2) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of these 27 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

What “Long-term cohort studies” covers

Long-term cohort studies — Large groups of people followed for years, tracking who develops dementia and what came before it.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Nature medicine 2024-05-14

GRN mutations cause progranulin haploinsufficiency, which eventually leads to frontotemporal dementia (FTD-GRN). 4 key findings →

Design: clinical trial Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of social isolation and loneliness with risk of incident hospital-treated infections: an analysis of data from the UK Biobank and Finnish Health and Social Support studies

✓ Peer-reviewed alzhub usefulness score 68 out of 100. The Lancet. Public health 2023-01-17

Although loneliness and social isolation have been linked to an increased risk of non-communicable diseases such as cardiovascular disease and dementia, their association with the risk of severe infection is uncertain. 4 key findings →

Design: cohort study Participants: 905 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Nature aging 2020-11-30

We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI) using plasma biomarkers of β-amyloid (Aβ), tau and neurodegeneration. 4 key findings →

Design: longitudinal study Participants: 573 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Brain : a journal of neurology 2020-12-01

Neurofilament light (NfL) is a marker of neuroaxonal injury, a prominent feature of Alzheimer's disease. 4 key findings →

Design: cross-sectional Participants: 1,149 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predicting Alzheimer's disease progression using deep recurrent neural networks

✓ Peer-reviewed alzhub usefulness score 65 out of 100. NeuroImage 2020-08-04

Early identification of individuals at risk of developing Alzheimer's disease (AD) dementia is important for developing disease-modifying therapies. 4 key findings →

Design: cross-sectional Participants: 1,677 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Acta neuropathologica 2019-05-27

The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer's disease risk (AD). 4 key findings →

Participants: 53,627 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2021-08-02

Plasma proteins affect biological processes and are common drug targets but their role in the development of Alzheimer's disease and related dementias remains unclear. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The relationship between sleep duration, cognition and dementia: a Mendelian randomization study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. International journal of epidemiology 2019-06-01

Linear MR suggested that each additional hour/day of sleep was associated with 1% [95% confidence interval (CI) = 0-2%; P = 0.008] slower reaction time and 3% more errors in visual-memory test (95% CI = 0-6%; P = 0.05). 4 key findings →

Participants: 395 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of neurology, neurosurgery, and psychiatry 2020-10-01

We identified individuals with an incident diagnosis of PD (n=1276) and controls (n=500 406) in UK Biobank. 4 key findings →

Participants: 1,276 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Type 2 Diabetes, According to the Number of Risk Factors Within Target Range, With Structural Brain Abnormalities, Cognitive Performance, and Risk of Dementia

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Diabetes care 2021-09-29

Type 2 diabetes is associated with increased risks of cognitive dysfunction and brain abnormalities. 4 key findings →

Participants: 10,663 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia

✓ Peer-reviewed alzhub usefulness score 58 out of 100. European journal of nuclear medicine and molecular imaging 2021-02-01

We analyzed data from 462 ADNI participants without dementia who underwent Aβ ([ 18 F]florbetapir or [ 18 F]florbetaben) and tau ([ 18 F]flortaucipir) PET, structural MRI, and cognitive testing. 4 key findings →

Design: cross-sectional Participants: 156 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Development and validation of a dementia risk score in the UK Biobank and Whitehall II cohorts

✓ Peer-reviewed alzhub usefulness score 57 out of 100. BMJ mental health 2023-07-01

Current dementia risk scores have had limited success in consistently identifying at-risk individuals across different ages and geographical locations. 4 key findings →

Participants: 176 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Outdoor physical activity, residential green spaces and the risk of dementia in the UK Biobank cohort

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Communications Medicine 2025-09-17

Outdoor activity is linked to lower dementia risk, particularly in those living in more accessible GS. 5 key findings →

Design: longitudinal study Participants: 187,724 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of social isolation, loneliness and genetic risk with incidence of dementia: UK Biobank Cohort Study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. BMJ open 2022-02-23

Social isolation and loneliness have been associated with increased risk of dementia, but it is not known whether this risk is modified or confounded by genetic risk of dementia. 4 key findings →

Participants: 70 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Alzheimer's research & therapy 2021-01-08

Recent studies suggest that plasma phosphorylated tau181 (p-tau181) is a highly specific biomarker for Alzheimer's disease (AD)-related tau pathology. 4 key findings →

Participants: 818 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2022-12-14

Baseline tau-PET and a composite baseline cognitive score were the strongest independent predictors of cognitive decline. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Ordinal SuStaIn: Subtype and Stage Inference for Clinical Scores, Visual Ratings, and Other Ordinal Data

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in artificial intelligence 2021-08-12

Subtype and Stage Inference (SuStaIn) is an unsupervised learning algorithm that uniquely enables the identification of subgroups of individuals with distinct pseudo-temporal disease progression patterns from cross-sectional datasets. 4 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study

✓ Peer-reviewed alzhub usefulness score 47 out of 100. JAMA cardiology 2022-09-01

Cholesteryl ester transfer protein inhibition (CETP) has been shown to increase levels of high-density lipoprotein cholesterol (HDL-C) and reduce levels of low-density lipoprotein cholesterol (LDL-C). 4 key findings →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed